Unasnemab
Based on 1 Customer Validation
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.00%
- CAS 番号: 2379805-59-9
- 分子量:144.88 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human IgG1 kappa
Human
RGMA
Unasnemab (48 h) significantly alleviated the reduction in average neurite length of NB-1 human neuronal cells cocultured with Tax-expressing JPX9 cells (a Tax-inducible cell line) in a dose-dependent manner[1].
Unasnemab (0.001-10 μg/mL, 72 h) significantly reversed the increased concentration of neurofilament light chain (NF-L) in the culture medium of NB-1 cells cocultured with PBMCs with HTLV-1-associated myelopathy (HAM) in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unasnemab (10 mg/kg, i.p., twice weekly, starting 3 days post-surgery for a total of 9 injections) significantly ameliorates bilateral common carotid artery stenosis (BCAS)-induced pathological changes and cognitive deficits in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-week-old db/db mice (type 2 diabetes model) and STZ-induced type 1 diabetic 8-week-old C57BL/6JJmsSlc mice[2]
-
Dosage:30 mg/kg
-
Administration:i.v., once weekly, 6 weeks
-
Result:Increased the number and density of DCX-positive immature neurons in the hippocampal granular cell layer (GCL), and improved their morphological defects.
Significantly increased the Discrimination Index (DI) in both Novel Object Recognition Test (NORT) and Object Placement Test (OPT) to restore hippocampus-dependent memory.
Showed no significant effects on STZ-induced body weight loss and blood glucose elevation.
-
Animal Model:Adult male C57BL/6J mice (8-10 weeks old) were used to establish the vascular dementia (VaD) model via bilateral common carotid artery stenosis (BCAS)[3]
-
Dosage:10 mg/kg
-
Administration:i.p., twice weekly, starting 3 days post-surgery for a total of 9 injections
-
Result:Reversed the reduction of doublecortin (DCX)-positive immature neurons in the hippocampal granular cell layer (GCL) and subgranular zone (SGZ).
Decreased the number of cleaved caspase-3/DCX double-positive apoptotic cells.
Promoted the survival and maturation of newborn neurons.
Attenuated the loss of cholinergic innervation in the hippocampal dentate gyrus.
Improved cognitive function.
Did not affect cerebral blood flow (CBF) in BCAS mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Q96B86-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Loaded Unasnemab on AHC2 biosensor, can bind RGMA Protein, Human (HEK293, His, HY-P76572) with an affinity constant of 1.418E-08 M as determined in BLI assay.
化学情報
-
CAS 番号 2379805-59-9
-
性状 Liquid
-
分子量 144.88 kDa
-
Color Colorless to light yellow
-
SMILES
[Unasnemab]
-
別名
MT-3921; rH116A3
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Araya N, et al. Virus-induced RGMa expression drives neurodegeneration in HTLV-1-associated myelopathy. JCI Insight. 2025 Apr 24;10(11):e184530. [Content Brief]
[2]. Uno H, et al. Inhibition of repulsive guidance molecule A ameliorates diabetes-induced cognitive decline and hippocampal neurogenesis impairment in mice. Commun Biol. 2025 Feb 19;8(1):263. [Content Brief]
[3]. Yamamoto M, et al. Anti-RGMa neutralizing antibody ameliorates vascular cognitive impairment in mice. Neurotherapeutics. 2025 Mar;22(2):e00500. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Unasnemab 関連分類
HY-P99959 関連分類
Powered by Bioz